Zymeworks Clears Key Benchmark, Hitting 90-Plus RS Rating
Zymeworks recently surpassed a crucial threshold by earning a 90-plus IBD Relative Strength Rating, reflecting strong share-price performance. The biotech and pharmaceutical company now stands out in the industry for its notable momentum.
2 days ago
1 min read